Phrenix Therapeutics is creating next‑generation medicines that rebalance dopaminergic signaling across specific brain circuits implicated in schizophrenia and related neuropsychiatric disorders. Their lead program aims to address the full spectrum of schizophrenia symptoms while offering an improved safety profile compared with existing treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Current antipsychotic medications for schizophrenia often provide limited relief for negative and cognitive symptoms and are associated with significant side effects due to non‑selective dopamine blockade across the brain.
Solution
Phrenix Therapeutics is creating next‑generation medicines that selectively rebalance dopaminergic signaling within specific neural circuits implicated in schizophrenia and related neuropsychiatric disorders. By focusing on circuit‑level pharmacology, the lead program aims to treat the full spectrum of schizophrenia symptoms—including positive, negative, and cognitive domains—while reducing adverse effects common to existing antipsychotics. The approach leverages precise receptor targeting and pharmacokinetic profiles to achieve therapeutic efficacy with an improved safety margin.
Target Audience
Primary customers are pharmaceutical companies and clinical research organizations developing treatments for schizophrenia and related neuropsychiatric disorders.
Features
- Circuit‑focused dopamine modulation that targets brain regions driving schizophrenia pathology
- Selective receptor engagement to minimize off‑target activity and associated side effects
- Dual efficacy on positive and negative symptom domains, addressing unmet clinical needs
- Optimized pharmacokinetic properties for consistent brain exposure and reduced dosing frequency
- Preclinical validation demonstrating balanced dopaminergic signaling and tolerability